Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4440056
Max Phase: Preclinical
Molecular Formula: C18H27BFN3O6
Molecular Weight: 411.24
Molecule Type: Unknown
Associated Items:
ID: ALA4440056
Max Phase: Preclinical
Molecular Formula: C18H27BFN3O6
Molecular Weight: 411.24
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)CC(NC(=O)C(CC(C)C)NC(=O)c1ccc(F)c([N+](=O)[O-])c1)B(O)O
Standard InChI: InChI=1S/C18H27BFN3O6/c1-10(2)7-14(18(25)22-16(19(26)27)8-11(3)4)21-17(24)12-5-6-13(20)15(9-12)23(28)29/h5-6,9-11,14,16,26-27H,7-8H2,1-4H3,(H,21,24)(H,22,25)
Standard InChI Key: IZYFKBSMYSIBHP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 411.24 | Molecular Weight (Monoisotopic): 411.1977 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Tan J, Grouleff JJ, Jitkova Y, Diaz DB, Griffith EC, Shao W, Bogdanchikova AF, Poda G, Schimmer AD, Lee RE, Yudin AK.. (2019) De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX., 62 (13): [PMID:31187989] [10.1021/acs.jmedchem.9b00878] |
2. Tan J, Grouleff JJ, Jitkova Y, Diaz DB, Griffith EC, Shao W, Bogdanchikova AF, Poda G, Schimmer AD, Lee RE, Yudin AK.. (2019) De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX., 62 (13): [PMID:31187989] [10.1021/acs.jmedchem.9b00878] |
Source(1):